Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
M. Restrepo, E. Mortensen, L. Copeland, B. Nakashima, M. Pugh, A. Anzueto (San Antonio, Temple, United States Of America). Macrolide therapy is associated with lower 30-day mortality in patients with non-pneumonia and pneumonia severe sepsis. Eur Respir J 2011; 38: Suppl. 55, 2554

Member's Comments

No comment yet.

Related content which might interest you: Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Impact of macrolide therapy on mortality in severe sepsis caused by pneumonia Source: Eur Respir J 2009; 33: 521 Year: 2009 Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients Source: Eur Respir J 2015; 45: 463-472 Year: 2015 Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2 Source: Eur Respir J, 56 (3) 2002439; 10.1183/13993003.02439-2020 Year: 2020 Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2 Source: Eur Respir J, 56 (3) 2002961; 10.1183/13993003.02961-2020 Year: 2020 Azithromycin is associated with improved survival in patients with healthcare-associated pneumonia Source: International Congress 2017 – Update on community acquired pneumonia Year: 2017 Is COPD pharmacotherapy associated with increased incidence of community-acquired pneumonia? Source: Annual Congress 2008 - Community-acquired pneumonia and COPD: what do we know? Year: 2008 COPD is associated with increased mortality in patients with community-acquired pneumonia Source: Eur Respir J 2006; 28: 346-351 Year: 2006 Predictive factors of in-hospital mortality of patients with community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 352s Year: 2006 On improving assessment of in-hospital mortality and ICU admisison in community-acquired pneumonia patients by using the e-CURB Source: Annual Congress 2012 - Respiratory infections: prognosis and outcome Year: 2012 Incidence of severe sepsis as a cause of clinical failure in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2007; 30: Suppl. 51, 42s Year: 2007 Intrahospital cardiovascular complications in severe community-acquired pneumonia Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis   Year: 2017 The impact of comorbidities on the in-hospital mortality in patients with community-acquired pneumonia Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management Year: 2015 Statin therapy and reduced risk of pneumonia in elderly patients with diabetes Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 The incidence and mortality rate of ventilator-associated pneumonia in elderly patients Source: Eur Respir J 2002; 20: Suppl. 38, 476s Year: 2002 Factors associated with community-acquired pneumonia in-hospital mortality in Portugal Source: Virtual Congress 2021 – Epidemiology and burden of tuberculosis and other lung diseases Year: 2021 The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 733s Year: 2006 Factors associated with one-year mortality in hospitalized patients with exacerbation of bronchiectasis. Source: Virtual Congress 2020 – New investigations of bronchiectasis and non-tuberculous mycobacteria Year: 2020 Causes and predictors of treatment failures in patients with ICU-acquired pneumonia Source: Eur Respir J 2002; 20: Suppl. 38, 16s Year: 2002 Inflammatory responses predict long-term mortality risk in community-acquired pneumonia Source: Eur Respir J 2011; 37: 1439-1446 Year: 2011